76 related articles for article (PubMed ID: 1827183)
1. [GM-CSF can reveal a latent infection].
Bastion Y; Coiffier B; Tigaud JD; Bryon PA
Presse Med; 1991 Mar; 20(10):477-8. PubMed ID: 1827183
[No Abstract] [Full Text] [Related]
2. [Pyoderma gangrenosum aggravated by GM-CSF administration].
Perrot JL; Benoit F; Segault D; Jaubert J; Guyotat D; Claudy A
Ann Dermatol Venereol; 1992; 119(11):846-8. PubMed ID: 1301698
[No Abstract] [Full Text] [Related]
3. Granulocyte-macrophage colony-stimulating factor in the management of severe ecthyma gangrenosum related to myelodysplastic syndrome.
Bécherel PA; Chosidow O; Berger E; Martin S; Khayat D; Herson S; Francès C
Arch Dermatol; 1995 Aug; 131(8):892-4. PubMed ID: 7632059
[No Abstract] [Full Text] [Related]
4. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
[TBL] [Abstract][Full Text] [Related]
5. Hemophagocytosis exacerbated by G-CSF/GM-CSF treatment in a patient with myelodysplasia.
Wang S; Degar BA; Zieske A; Shafi NQ; Rose MG
Am J Hematol; 2004 Dec; 77(4):391-6. PubMed ID: 15551287
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of human granulocyte-macrophage colony-stimulating factor.
Sakamoto KM; Gasson JC
Int J Cell Cloning; 1991 Nov; 9(6):531-41. PubMed ID: 1770227
[TBL] [Abstract][Full Text] [Related]
7. [GM-CSF and G-CSF: cytokines in clinical application].
Ruef C; Coleman DL
Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
[TBL] [Abstract][Full Text] [Related]
8. [Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia].
Lehrnbecher T
Klin Padiatr; 2001; 213(4):212-38. PubMed ID: 11528556
[TBL] [Abstract][Full Text] [Related]
9. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
10. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
11. Effect of in vivo treatment with rh GM-CSF on in vitro growth of haematopoietic progenitors in patients with myelodysplastic syndromes.
Visani G; Tosi P; Finelli C; Gamberi B; Zauli G; Cenacchi A; Fogli M; Colombini R; Tura S
Haematologica; 1992; 77(2):142-5. PubMed ID: 1383105
[TBL] [Abstract][Full Text] [Related]
12. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases.
Rose C; Wattel E; Bastion Y; Berger E; Bauters F; Coiffier B; Fenaux P
Leukemia; 1994 Sep; 8(9):1458-62. PubMed ID: 8090025
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
14. GM-CSF treatment of myelodysplastic syndromes: personal experience and preliminary results of a randomized international study.
Coiffier B; Bastion Y; Felman P; Tigaud JD; Bryon PA
Pathol Biol (Paris); 1992 Nov; 39(9):957-8. PubMed ID: 1538951
[No Abstract] [Full Text] [Related]
15. [Increase of neopterin after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)].
Melichar B; Solichova D; Jebavy L
Presse Med; 1994 Mar; 23(12):581. PubMed ID: 8066063
[No Abstract] [Full Text] [Related]
16. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
17. Emerging clinical uses for GM-CSF.
Scarffe JH
Eur J Cancer; 1991; 27(11):1493-504. PubMed ID: 1835868
[No Abstract] [Full Text] [Related]
18. Treatment of myelodysplastic syndromes with hematopoietic growth factors.
Ganser A; Hoelzer D
Hematol Oncol Clin North Am; 1992 Jun; 6(3):633-53. PubMed ID: 1377194
[TBL] [Abstract][Full Text] [Related]
19. [G-CSF versus GM-CSF in the treatment of neutropenia in a patient with Felty's syndrome on hemodialysis].
del Pozo C; Ortiz de Salazar MI; Torregrosa I; Sánchez L; Albero MD; Bauza J
Nefrologia; 2000; 20(5):455-8. PubMed ID: 11100668
[TBL] [Abstract][Full Text] [Related]
20. [Granulocyte and macrophage colony stimulating factor (GM-CSF) in patients with acquired immunodeficiency syndrome and neutropenia].
Martos A; Domínguez MA; Martínez Lacasa J; Podzamczer D
Med Clin (Barc); 1992 Jun; 99(5):196-7. PubMed ID: 1507903
[No Abstract] [Full Text] [Related]
[Next] [New Search]
